When should we measure Vitamin D concentration in clinical practice?

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 72, Issue SUPPL. 243, 2012, Pages 129-135

  Souberbielle, Jean Claude ^a   Courbebaisse, Marie ^b   Cormier, Catherine ^c   Pierrot Deseilligny, Charles ^d   Viard, Jean Paul ^e   Jean, Guillaume ^f   Cavalier, Etienne ^g  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c université Paris Cité   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔTEL DIEU   (France)

^f Centre de Rein Artificiel de Tassin   (France)

^g UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

25 hydroxyvitamin D; Chronic kidney disease; Osteoporosis; Vitamin D deficiency

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; 25-HYDROXYVITAMIN D; DRUG DERIVATIVE; VITAMIN D;

ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; FALLING; GRAFT RECIPIENT; GRANULOMATOSIS; HORMONE BLOOD LEVEL; HUMAN; INFORMATION PROCESSING; KIDNEY GRAFT; MALABSORPTION; MINERAL METABOLISM; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PAIN; PRESCRIPTION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RICKETS; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; BLOOD;

HUMANS; OSTEOMALACIA; RICKETS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84860358760     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2012.682888     Document Type: Article

References (44)

1. Holick M, Binkley N, Bischoff-Ferrari H,Gordon C, Hanley D, et al. Evaluation, treatment and prevention of vitamin D defi ciency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-1930.
2. Ross C, Manson JE, Abrams S, Aloia J, Brannon P, Clinton S, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 2011;96:53-58.
3. Norman A. Vitamin D nutrition is at a crossroads. Public Health Nutrition 2011;14:750-751.
4. Adams J, Hewison M. Update in vitamin D. J Clin Endocrinol Metab 2010;95:471-478.
5. Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burckardt P, Fuleihan GEH, et al. IOF position statements: Vitamin D recommendations for older adults. Osteoporos Int 2010;21:1151-1154.
6. Perez-Lopez F, Brincat M, Erel T, Erel T, Tremollieres F, Gambacciani M, et al. EMAS position statement: Vitamin D and postmenopausal health. Maturitas 2012;71:194-198.
7. Vieth R. Why the optimal requirement for vitamin D3 is probably much higher than what is offi cially recommended for adults. J Steroid Biochem Mol Biol 2004;89: 575-579.
8. Bischoff-Ferrari H, Giovanucci E, Willett W, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple outcomes. Am J Clin Nutr 2006;84:18-28.
9. Dawson-Hughes B, Heaney R, Holick M, Lips P, Meunier P, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-716.
10. Hanley D, Cranney A, Jones G, Whiting S, Leslie W, Cole D, et al. Vitamin D in adult health and disease: A review and guideline statement from Osteoporosis Canada. CMAJ 2010;182:E610-E618.
11. Souberbielle JC, Body JJ, Lappe J, Plebani M, Schoenfeld Y, Wang T, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmunity Reviews 2010; 9:709-715.
12. Mithal A, Wahl DA, Bonjour JP, Burckardt P, Dawson-Hughes B, Eisman J, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;11:1807-1820.
13. Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol 2008;3:1535-1541.
14. Cashman K, Fitzgerald A, Kiely M, Seamans K. A systematic review and meta-regression analysis of the vitamin D intake-serum 25-hydroxyvitamin D relationship to inform European recommendations. Br J Nutr 2011;106: 1617-1627.
15. Leu M, Giovannucci E. Vitamin D: Epidemiology of cardiovascular risks and events. Best Practice & Research Clinical Endocrinology & Metabolism 2011;25:633-646.
16. Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. Association between vitamin D and risk of colorectal cancer: A systematic review of prospective studies. J Clin Oncol 2011;29: 3775-3782.
17. Munger K, Levin L, Hollis B, Howard N, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-28 38.
18. Bodnar L, Catov J, Simhan H, Holick M, Powers R, Roberts J. Maternal vitamin D defi ciency increases the risk of preeclampsia. J Clin Endocrinol Metab 2007;92:3517-3522.
19. Holick MF. Vitamin D defi ciency. N Engl J Med. 2007; 357:266-81.
20. Bischoff-Ferrari H. How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int 2007;18: 401-407.
21. Vieth R, Bischoff-Ferrari H, Boucher B, Dawson-Hughes B, Garland C, Heaney R, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 2007;85:649-650.
22. Heaney R, Davies M, Chen TC, Holick M, Barger-Lux J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003;77:204-210.
23. Yendt E, Kovacs K, Jones G. Secondary hyperparathyroidism in primary osteoporosis and osteopenia: Optimizing calcium and vitamin D intakes to levels recommended by expert panels may not be suffi cient for correction. Clinical Endocrinology 2008;69:855-863.
24. Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011;365:410-421
25. Bischoff-Ferrari H, Willett W, Wong J, Stuck A, Staehelin H, Orav J, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency. Arch Int Med 2009;169: 551-561.
26. Bischoff-Ferrari H, Dawson-Hughes B, Staehelin HB, Orav J, Stuck A, Theiler R, et al. Fall prevention with supplemental and active forms of vitamin D: A meta-analysis of randomised controlled trials. BMJ 2009;339:b3692.
27. Priemel M, von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, et al. Bone mineralization defects and vitamin D defi ciency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2010;25:305-312.
28. Okazaki R, Sugimoto T, Kaji H, Fujii Y, Shiraki M, Inoue D, et al. Vitamin D insuffi ciency defi ned by serum 25-hydroxyvitamin D and parathyroid hormone before and after oral vitamin D3 supplementation load in Japanese patients. J Bone Miner Metab 2011;29:103-110.
29. Cavalier E, Rozet E, Gadisseur R, Carlisi A, Monge M, Chapelle JP, et al. Measurement uncertainty of 25-OH vitamin D determination with different commercially available kits: Impact on the clinical cut-offs. Osteoporos Int 2010;21:1047-1051.
30. Edwards BJ, Langman CB, Bunta AD, Vicuna M, Favus M. Secondary contributors to bone loss in osteoporosis related hip fractures. Osteoporos Int 2008;19:991-999.
31. Davidson Z, Walker K, Truby H. Do glucocorticoids alter vitamin D status? A systematic review with meta-analyses of observational studies. J Clin Endocrinol Metab 2012;97 (in press).
32. Camacho P, Dayal A, Diaz J, Nabhan F, Agarwal M, Norton J, et al. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. J Clin Oncol 2008;26:5380-5385.
33. KDIGO. Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney diseasemineral and bone disorder (CKD-MBD). Kidney Int 2009; 79:S1-S130.
34. Kandula P, Dobre M, Schold JD, Schreiber M, Mehrotra R, Navaneethan S. Vitamin D supplementation in chronic kidney disease: A systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011;6:50-62
35. Jean G, Souberbielle JC, Chazot C. Strategy for vitamin D supplementation. Monthly cholecalciferol administration in hemodialysis patients: A simple and effi cient strategy for vitamin D supplementation. Nephrol Dial Transplant 2009;24: 3799-3805.
36. Matias PJ, Jorge C, Ferreira C, Borges C, Aires I, Amaral T, et al. Cholecalciferol supplementation in hemodialysis patients: Effects on mineral metabolism, infl ammation, and cardiac dimensions parameters. Clin J Am Soc Nephrol 2010;5:905-911.
37. Courbebaisse M, Thervet E, Souberbielle JC, Zuber J, Eladari D, Martinez F, et al. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int 2009;75:646-651.
38. Pilz S, Iodice S, Zittermann A, Grant W, Gandini S. Vitamin D status and mortality risk in CKD: A metaanalysis of prospective studies. Am J Kidney Dis 2011;58: 374-382.
39. de Boer IH, Katz R, Chonchol M, Sarnak M, Shlipak M, Siskovick D, et al. Serum 25-hydroxyvitamin D and change in estimated glomerular fi ltration rate. Clin J Am Soc Nephrol 2011;6:2141-2149.
40. Kim MJ, Frankel A, Donaldson M, Darch S, Pusey C, Hill P, et al. Oral cholecalciferol decreases albuminuria and urinary TGF- 1 in patients with type 2 diabetic nephropathy on established renin-angiotensin- Aldosterone system inhibition. Kidney Int 2011;80:851-860.
41. Grey A, Lucas J, Horne A, Gamble G, Davidson J, Reid I. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insuffi ciency. J Clin Endocrinol Metab 2005;90:2122-2126.
42. Souberbielle JC, Maury E, Friedlander G, Cormier C. Vitamin D and primary hyperparathyroidism (PHPT). J Steroid Biochem Mol Biol 2010;121:199-203.
43. Eastell R, Arnold A, Brandi ML, Brown E, D' A mour P, Hanley D, et al. Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94: 340-350.
44. Lowe H, McMahon DJ, Rubin M, Bilezikian J, Silverberg S. Normocalcemic primary hyperparathyroidism: Further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007;92:3001-3005.